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N-methyl-D-aspartate receptor (NMDAR) modulators induce rapid and sustained
antidepressant like-activity in rodents through a molecular mechanism of action that
involves the activation of Ca2+ dependent signaling pathways. Moreover, ketamine, a
global NMDAR antagonist is a potent, novel, and atypical drug that has been successfully
used to treat major depressive disorder (MDD). However, because ketamine evokes
unwanted side effects, alternative strategies have been developed for the treatment of
depression. The objective of the present study was to determine the antidepressant
effects of either a single dose of hyperforin or lanicemine vs. their combined effects
in mice. Hyperforin modulates intracellular Ca2+ levels by activating Ca2+-conducting
non-selective canonical transient receptor potential 6 channel (TRPC6) channels.
Lanicemine, on the other hand, blocks NMDARs and regulates Ca2+ dependent
processes. To evaluate the antidepressant-like activity of hyperforin and lanicemine,
a set of in vivo (behavioral) and in vitro methods (western blotting, Ca2+ imaging
studies, electrophysiological, and radioligand binding assays) was employed. Combined
administration of hyperforin and lanicemine evoked long-lasting antidepressant-like
effects in both naïve and chronic corticosterone-treated mice while also enhancing
the expression of the synapsin I, GluA1 subunit, and brain derived neurotrophic factor
(BDNF) proteins in the frontal cortex. In Ca2+ imaging studies, lanicemine enhanced
Ca2+ influx induced by hyperforin. Moreover, compound such as MK-2206 (Akt kinase
inhibitor) inhibited the antidepressant-like activity of hyperforin in the tail suspension
test (TST). Hyperforin reversed disturbances induced by MK-801 in the novel object
recognition (NOR) test and had no effects on NMDA currents and binding to NMDAR. Our
results suggest that co-administration of hyperforin and lanicemine induces long-lasting
antidepressant effects in mice and that both substances may have different molecular
targets.
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INTRODUCTION
Chronic intake, delayed onset of action, drug resistance, and
numerous side effects of current antidepressants have forced
researchers to look for new and safer drugs with rapid onset
and longer acting times (Rosenblat et al., 2015; Sanacora
and Schatzberg, 2015). Results obtained in recent years have
been encouraging, especially with ketamine, a global NMDAR
antagonist. The antidepressant-like activity of ketamine has been
shown in many preclinical studies (Maeng et al., 2008; Li et al.,
2010, 2011; Autry et al., 2011; Gideons et al., 2014; Miller et al.,
2014). A single non-anesthetic dose of ketamine reversed the
symptoms of MDD (Berman et al., 2000). The antidepressant
effects of ketamine were also observed in patients who suffered
from treatment-resistant depression or suicidal ideations (Zarate
et al., 2006a; DiazGranados et al., 2010; Murrough et al.,
2013; Price et al., 2014). Despite successful clinical trials with
ketamine, its use on a large scale is fraught with difficulties
and is controversial. Ketamine can induce unwanted side effects
such as psychotomimetic symptoms and cognitive disturbances
(Rajagopal et al., 2016).
Therefore, other NMDAR antagonists have been tested.
Unfortunately, clinical trials with low trapping NMDAR
antagonists such as lanicemine (Sanacora et al., 2014, 2017)
and other global NMDAR antagonists like memantine (Zarate
et al., 2006b) have given inconsistent results and do not
show ketamine-like antidepressant potentials. Memantine and
lanicemine are also not as effective as ketamine in preclinical
studies (Gideons et al., 2014; Qu Y. et al., 2017). However,
the data from Preskorn et al. (2008) indicate that NMDA
blockade with traxoprodil, a selective antagonist of the
GluN2B subunit of the NMDA receptor also produces a
robust antidepressant effect. These observations were used
to formulate alternative hypotheses that NMDAR blockade
could not be the primary molecular mechanism of ketamine
action (Zanos et al., 2016, 2017; Collingridge et al., 2017).
Moreover, individual enantiomers of ketamine have been
shown to activate different intracellular signaling pathways
with the induction of different profiles of antidepressant-
like activity in mice (Yang et al., 2017, 2018b). Despite all
these controversies and doubts surrounding ketamine’s primary
mode of action, it has been shown that its antidepressant
activity in animals is causally dependent on the enhanced
processes of neuroplasticity induced in brain regions like the
prefrontal cortex (PFC) and hippocampus (Hp) (Li et al.,
2010, 2011; Ardalan et al., 2017). At the molecular level, these
processes are dependent on the interplay between glutamate
receptors, Ca2+ channels, intracellular Ca2+ levels, Ca2+-
dependent proteins like Akt, ERK, mTOR, and neurotrophins
such as BDNF (Duman and Voleti, 2012; Duman et al., 2016;
Workman et al., 2018). The role of Ca2+ homeostasis in the
antidepressant activity of ketamine was recently reported by
Yang et al. (2018a). They showed that the local blockade of
NMDAR by ketamine or blockade of the low voltage-sensitive
T-type calcium channels (T-VSCC) by mibefradil in the lateral
habenula induced antidepressant-like effects in rats (Yang et al.,
2018a).
Because Ca2+ is the focal point to all the processes mentioned
above, we have focused our study on hyperforin, a Ca2+-
modulator. Hyperforin is the natural and biologically active
compound extracted from Hypericum perforatum (St John’s
Wort) (Cervo et al., 2002). Both St John’s Wort and hyperforin
attenuated symptoms of mild to moderate depression in
several clinical trials and displayed antidepressant-like activity
in preclinical studies (Zanoli, 2004). Hyperforin also restored
cognitive abilities in rats subjected to chronic stress (Liu et al.,
2015).
From a molecular perspective, hyperforin has a multi-
directional mechanism of action. It blocks conductance of ligand-
gated (GABA, NMDA, and AMPA receptors) (Chatterjee et al.,
1999; Kumar et al., 2006) and voltage-gated channels (Ca2+, K+,
andNa+) (Chatterjee et al., 1999; Fisunov et al., 2000). In contrast
to blockade of ion transport through the plasma membrane,
hyperforin can generate inward Ca2+ currents. In vitro studies
have shown that hyperforin increases intracellular Ca2+ levels by
activating TRPC6 or by releasing Ca2+ from the mitochondria
(Leuner et al., 2007; Tu et al., 2009, 2010). Thus, hyperforin is a
potent modulator of intracellular Ca2+ levels. Heiser et al. (2013)
showed that hyperforin increased the activity of RAS/MEK/ERK
and PI3K/Akt or CAMKIV intracellular signaling pathways in
PC12 cells and hippocampal CA1 neurons. Gibon et al. (2013)
also showed that hyperforin enhanced the expression of TrkB
(BDNF receptor), c-AMP response binding-protein (CREB) and
the phosphorylated form of CREB (p-CREB) in primary cortical
neurons including TrkB in the cortex of adult mice.
It has been shown that in vitro (Heiser et al., 2013), hyperforin
activates Ca2+-dependent signaling pathways involved in
neuroplasticity akin to ketamine and NMDAR antagonists,
which are known to activate Ca2+-dependent signaling pathways
in vivo (Duman and Voleti, 2012). In addition, Qu et al. recently
described a functional relationship between NMDAR and
TRPC6. They showed that TRPC6 expression is regulated by
NMDAR in vitro (Qu Z. et al., 2017). Based on this, we asked the
following question: “Can a single dose of hyperforin potentiate
antidepressant-like activity a single dose of NMDAR antagonists
in mice and what is the mechanism of action?”
To answer this question we selected two NMDAR antagonists:
lanicemine and MK-801. In the first phase of the study,
we determined whether there was an interaction between
NMDAR and hyperforin using TST in naïve mice. Secondly, we
determined the effects of the combined administration of a single
dose of hyperforin and lanicemine in mice exposed to chronic
corticosterone treatment.
Because hyperforin’s potential to improve cognitive activity
has been described elsewhere (Klusa et al., 2001; Liu et al.,
2015), in the next part of our study we evaluated hyperforin’s
potential to attenuate cognitive deficits induced by MK-801
in the NOR test. This is a very important area of research,
because ketamine and other NMDAR antagonists can induce
cognitive deficits (Rajagopal et al., 2016) which are also present
in MDD (Lam et al., 2014), Next, we determined whether
hyperforin’s antidepressant-like activity was dependent on select
Ca2+signaling pathways and the glutamate system. The last
phase of the study was devoted to determining the potential
Frontiers in Molecular Neuroscience | www.frontiersin.org 2 December 2018 | Volume 11 | Article 456
Pochwat et al. Antidepressant-Like Activity of Hyperforin and Lanicemine
biochemical and electrophysiological mechanisms induced by
hyperforin and lanicemine.
MATERIALS AND METHODS
Animals
Male and female adult (9–10 weeks, 23–25 g) C57BL/6J mice
(Charles River) were used in the experiments. Mice were housed
under a natural 12 h light/dark cycle in a room with controlled
temperature with ad libitum access to water and food. All
behavioral experiments were performed between 9 a.m. and 2
p.m. All studies were performed according to the guidelines
of the European Community Council (Directive 86/609/EEC)
and were approved by the Ethical Committee of the Institute of
Pharmacology.
Compounds and Treatment
All the compounds/drugs used in the study were obtained
commercially except hyperforin (sodium salt), which was a gift
from Dr. Wilmar Schwabe GmbH & Co (Karlshrue Germany).
Doses of compounds were chosen based on results from
our preliminary studies (lanicemine and hyperforin) or from
literature (MK-801, fluoxetine, NMDA). Pertinent information
on the various compounds is presented in Table 1.
Cannulae Implantation
For intracerebroventricular (i.c.v.) injection of compounds, mice
were anesthetized with ketamine (100 mg/kg i.p.) and xylazine
(10 mg/kg i.p.; Biowet, Poland) and stereotaxically, bilaterally
implanted with the guide cannulae (8mm); (coordinates relative
to bregma: 1mm lateral, 0.2mm posterior and 3,7mm ventral).
After 14 days of recovery, mice were subjected to injection and
behavioral studies. Compounds were applied to each ventricle
for 1min, followed by a 1min diffusion time. Mice received one
injection each through both ventricles (1 µL per ventricle) using
an infusion cannula (9mm) 15min before i.p. hyperforin (2.5
mg/kg) administration. 1 h after hyperforin treatment TST was
conducted.
Chronic Exposure to Corticosterone
Male C57BL/6J mice (10 weeks old) which included controls and
Cort-treated (Cort) groups were housed 6 per cage. The Cort
group received corticosterone (25µg/ml) in drinking water for
the first 4 weeks. Corticosterone (Sigma Aldrich) was dissolved
in concentrated ethanol and added to the drinking water to give a
final concentration of 0.5%. Controls, only received 0.5% ethanol
in drinking water. All bottles were wrapped in foil and replaced
every 3 days. In the 5th week, corticosterone concentration was
gradually reduced as follows: Cort group received 12.5µg/ml of
corticosterone in the first 3 days followed by 6.25µg/ml in the
next 3 days.
Animals were Cort free during the next 7 days, after which
behavioral tests were carried out. All behavioral tests were
performed on the same mice. Administration of Cort in drinking
water has been described in several papers (Gourley et al., 2008;
Miller et al., 2014; Zanos et al., 2016).
Forced Swim Test
The Forced swim test (FST) was conducted as previously
described (Szewczyk et al., 2010). Mice were put individually
in a glass cylinder (10 cm diameter, 25 cm high) filled with
water (23–25◦C) to the height of 10 cm for 6min. Following
that, immobility time was measured in the last 4min of the
experiment. Mice that remained floating passively were judged
to be immobile.
Tail Suspension Test
TST was conducted as previously described (Steru et al., 1985).
Briefly, each mouse was individually suspended by the tail, using
adhesive tape (2 cm from the tail tip) glued to a solid flat surface.
Immobility time was measured for 6min. A mouse was judged
to be immobile when it was hanging passively and completely
motionless.
Locomotor Activity
Evaluation of the specificity of the effects observed in the FST
and TST was assessed by locomotor activity (Table 2). Plexiglas
locomotor activity chambers (40 × 20 × 15 cm) in a 20-station
photo-beam activity system (Columbus Instruments, Opto-M3-
activity meter) were used to measure locomotor activity. Each
mouse was placed individually in the chamber for a 6min session
during which the total number of ambulations was measured.
Splash Test
A Splash test was conducted as described by Yalcin et al. (2008).
Briefly, 10% sucrose solution was sprayed on the back of each
mouse. The viscous nature of the solution induces enhanced
grooming behavior. Each session lasted 5min with grooming
behavior measured accordingly.
Novel Object Recognition Test
This test was conducted as previously described (Wozniak et al.,
2016). In brief, training, habituation and test sessions took
place in a black plastic rectangular open field (50 × 30 ×
35 cm) illuminated by a 25W bulb. Habituation was carried
out for 10min for 2 days during which each mouse was placed
individually in the open field in the absence of objects and
allowed to explore the environment. Training and test sessions
were performed 24 h after habituation. In the first session (5min)
mice explored two identical objects (red glass cylinders 6.6 cm
in diameter and 4.5 cm high). During the second session (1 h
later), the familiar object was replaced by a novel object (a
transparent elongated sphere-like object with an orange cap,
5.5 cm in diameter, 8.5 cm high). Mice were allowed to explore
this environment for 5min. They were administered hyperforin
(30min interval) followed by MK-801 which was administered
30min before the first training session. Time spent exploring
(i.e., sniffing or touching) the familial (T familial) or novel
object (T novel) was measured by a trained observer followed
by calculation of the recognition index [(T familial–T novel)/(T
familial+ T novel)].
Western Blotting
Western blotting was conducted as previously described
(Szewczyk et al., 2014; Rafalo et al., 2017). Briefly, after
Frontiers in Molecular Neuroscience | www.frontiersin.org 3 December 2018 | Volume 11 | Article 456
Pochwat et al. Antidepressant-Like Activity of Hyperforin and Lanicemine
TABLE 1 | Pertinent information on the various compounds/drugs.
Compound Hyperforin
sodium salt
Lanicemine MK-2206 MK-801 Larixyl
acetate
NMDA Fluoxetine
Doses
mg/kg
1, 2.5; 5; 10
i.p.
2, 10
i.p.
20
i.p.
0.1; 0.3
i.p.
10 nM/2 µL
i.c.v
75
i.p.
10
i.p.
Solvent Aqua pro
injection
Aqua pro
injection
10%
DMSO
Aqua pro
injection
Phosphate
buffer + 1%
DMSO
Aqua pro-
injection
Aqua pro
injection
Source Wilmar
Schwabe
Sigma
Aldrich
Selleckchem Sigma
Aldrich
Sigma
Aldrich
Sigma
Aldrich
Selleckchem
i.p., intraperitoneal; i.c.v, intracerebroventricular.
TABLE 2 | The effect of used compounds and procedures on the locomotor
activity of mice.
Treatment mg/kg Locomotor activity
(% of control)
A. Control
Lanicemine 2
Lanicemine 2 + Hyperforin 1
Lanicemine 10
Lanicemine 10 + Hyperforin 5
100.0 ± 5.46
105.1 ± 9.16
129.2 ± 13.88
87.77 ± 4.70
82.8 ± 12.96
B. Control
MK-801
MK-801 + Hyperforin
100.0 ± 4.89
123.8 ± 15.24
76.44 ± 12.29#
C. Control
Hyperforin 2.5
Lanicemine
Fluoxetine
Lanicemine + Hyperforin
CORT
CORT + Hyperforin
CORT + Lanicemine
CORT + Fluoxetine
CORT + Lanicemine+Hyperforin
100.0 ± 7.21
91.74 ± 8.12
131.1 ± 13.97
104.2 ± 7.87
90.74 ± 12.2
122.9 ±6.45
90.88 ±9.60
130.2 ± 15.71
97.94 ± 2.35
101.6 ± 11.69
D. Control
Hyperforin 5
NMDA 75
NMDA 75 + Hyperforin 5
MK 2206
MK 2206 20 + Hyperforin 5
100.0 ± 3.16
55.83 ± 5.72**
69.25 ± 8.00*
57.01 ± 11.45**
82.99 ± 6.98
73.4 ± 6.67*
E. Control
Larixyl acetate 10nmol/2ul
Hyperforin 2.5
Larixyl acetate 10nmol/2ul + Hyperforin 2.5
100.0 ± 9.60
84.5 ± 9.51
87.97 ± 21.6
40.31 ± 10.81*
Locomotor activity wasmeasured immediately after TST. *p< 0.05; **p< 0.01 vs. Control;
#p < 0.05 vs. MK-801. Data was analyzed by one way ANOVA (A–D) or two way ANOVA
and Newman-Keuls multiple comparisons test. All values are expressed asmean± S.E.M.
(A) F(4,20) = 3.719; p = 0.02; (B) F(2, 12) = 4.191; p = 0.04; (C) [CORT: F(1,47) = 0.659;
p = 0.421; Treatment F(4, 47) = 4.476; p = 0.004; Interaction F(4,47) = 0.716; p = 0.585].
(D) F(5, 28) = 5.668; p = 0.001; (E) F(3, 13) = 3.766; p = 0.038. n = 4–6.
decapitation, the frontal cortex was rapidly dissected from
each mouse, frozen on dry ice and stored at −80◦C. Next,
tissue was homogenized in a 2% solution of sodium dodecyl
sulfate (SDS), denatured at 95◦C for 10min and centrifuged
for 5min at 10,000 rpm. The protein in the supernatant was
assayed by the bicinchoninic acid method (Pierce). Proteins
were fractionated on a 10 or 12% SDS polyacrylamide gel
and transferred to nitrocellulose membrane (Bio-Rad). Non-
specific binding was blocked by 1% blocking solution (BM
Chemiluminescence Western Blotting Kit Mouse/Rabit, Roche).
Following blocking, membranes were incubated overnight with
the following antibodies: BDNF (∼15 kD, 1:500, Monoclonal,
Santa Cruz), phosphorylated CREB (p-CREB); (∼43 kD, 1:1,000,
monoclonal, Millipore), GluA1-AMPA (∼100 kD, 1:1,000,
polyclonal, Abcam), Synapsin I (∼74 kD, 1:1,000, monoclonal,
Abcam,), total CREB (∼43 kD, 1:1,000. monoclonal, Santa
Cruz), β-actin (∼42 kD, 1:10,000, monoclonal, Sigma). The
next day, membranes were washed (3 times) with Tris-buffered
saline containing Tween (TBST) and incubated with secondary
mouse/rabbit antibodies (1:7,000, Roche). Finally, blots were
washed 3 times in TBST and incubated in the detection
reagent (Roche). The signal from each protein was measured
and visualized using the Fuji-Las 1000 system and Image
Gauge v 4.0. β-actin was used as a loading control and for
normalization (Figure S4). The densities of the bands obtained
for phosphorylated and total CREB were first normalized to
appropriate actin bands and then the ratio of normalized p-
CREB/CREB was calculated. Data on the graph are expressed as
% of change vs. control.
Whole Cell Patch Clamp Studies
Brain Slice Preparation for Patch Clamp Experiments
Mice were decapitated under isoflurane anesthesia (Aerrane,
Baxter) between 9 and 10 a.m. Brains were quickly removed
and placed in ice-cold artificial cerebrospinal fluid (aCSF)
containing (in mM): 130 NaCl, 5 KCl, 2.5 CaCl2, 1.3 MgSO4,
1.25 KH2PO4, 26 NaHCO3, and 10 D-glucose. Coronal slices
(300µm) containing the mPFC were cut using a vibrating
microtome (Leica VT1000) and subsequently incubated in
carbonated aCSF at 30± 0.5◦C for at least 1 h before recording.
Whole-Cell Patch Clamp Recording
To record NMDA currents, slices were placed in the recording
chamber superfused at 3 ml/min with warm (32 ± 0.5◦C),
modified Mg2+-free aCSF with the following composition
(in mM) 132 NaCl, 2 KCl, 2.5 CaCl2, 1.25 KH2PO4, 26
NaHCO3, 10 D-glucose, continuously bubbled with a mixture
of 95% O2 and 5% CO2. NBQX (5µM) was added to block
AMPA/kainate receptors. Neurons were visualized using a Zeiss
AxoExaminer.A1 upright microscope equipped with IR DIC
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optics, a 40× water immersion lens and an infrared camera
(Sony). Patch pipettes pulled from borosilicate glass capillaries
(Harvard Instruments) using a Sutter Instrument P97 puller had
open tip resistances of approximately 3–5 M when filled with
a solution containing (in mM): 130 K-gluconate, 5 NaCl, 0.3
CaCl2, 2 MgCl2, 10 HEPES, 5 Na2-ATP, 0.4 Na-GTP, and 1
EGTA. Osmolarity and pH were adjusted to 290 mOsm and 7.2,
respectively. Signals were recorded with the Multiclamp 700B
amplifier (Molecular Devices), filtered at 2 kHz and digitized
at 20 kHz using the Digidata 1,550 interface and pCLAMP 10
software (Molecular Devices).
Stimulation and Recording of NMDA Postsynaptic
Currents
Synaptic NMDA currents were evoked using a concentric
platinum/stainless steel electrode (FHC, USA) by stimulating
(every 30 s, duration 0.2ms) layer V of the mPFCwhile recording
from mPFC layer II/III pyramidal neurons in a voltage clamp
mode with a holding potential of −70mV. Stimulation intensity
was adjusted so that a stable NMDA current of approximately
100 pA could be recorded for at least 10min before drug
application.
Currents were percentage-normalized with reference to 5min
of the recording right before drug application. Percentage of
the response was measured by averaging 5 consecutive currents
after 10min of drug application. At this time the response to
lanicemine (2µM) treatment plateaued while the response to
hyperforin (0.5µM) remained stable.
Extracellular Field Potential Recordings
Mice were decapitated, their frontal cortices were dissected
and cut into 400 µm-thick slices which were stored in a
gassed (95% O2 and5% CO2) ACSF, consisting of (in mM):
127 NaCl, 5 KCl, 2.5 CaCl2, 1.3 MgSO4, 1.25 KH2PO4,
24NaHCO3, and 10 glucose. Individual slices were placed in the
recording chamber of an interface type which was superfused
(2.5 ml/min) with a modified ACSF, (temperature 32.0 ±
0.5◦C) containing (in mM) NaCl (132), KCl (2), CaCl2 (2.5),
KH2PO4 (1.25), NaHCO3 (26), and D-glucose (10), bubbled with
95% O2 and 5% CO2 (temperature 32.0 ± 0.5
◦C). To study
the NMDA receptor-mediated component of field potentials
(FP), the slices were perfused with ACSF devoid of Mg2+
ions and supplemented with 5µm of 2,3-dioxo-6-nitro-1,2,3,4-
tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX, Tocris
Bioscience), an AMPA receptor antagonist.
A concentric bipolar stimulating electrode (FHC, USA) was
placed in cortical layer V. The recording electrode was placed
in layers II/III of the mPFC (prelimbic cortex region). Stimuli
of 0.033Hz frequency and duration of 0.2ms were applied
using a constant-current stimulus isolation unit (WPI). Glass
micropipettes filled with ACSF (2–5 M) were used to record
field potentials. The responses were amplified (EXT 10–2 F
amplifier, NPI), filtered (1 Hz−1 kHz), A/D converted (10 kHz
sampling rate), and stored on PC using the Micro1401 interface
and Signal 4 software (CED).
After the 30min, of incubation and after stabilizing the
responses, a stimulus was adjusted to evoke a response of 40%
of the maximum amplitude. After 15min of baseline recording
a hyperforin 1 uM was added (20min) and recording was
continued for 70min.
Calcium Imaging
Primary cultures of cortical neurons were prepared from
embryonic (E13) C57BL6/J mice as previously described (Bouron
et al., 2005) and approved by the animal care committee
of the CEA’s Life Sciences Division (CEtEA). Experiments
were conducted in accordance with French legislation and the
European Community Council Directive of 24 November 1986
(86/609/EEC). Calcium imaging experiments were performed
at room temperature as previously described (Gibon et al.,
2013; Chauvet et al., 2015, 2016). Briefly, cortical neurons were
incubated in a saline solution containing (mM) 150 NaCl, 5 KCl,
1 MgCl2, 2 CaCl2, 5.5 glucose, 10 HEPES (pH 7.4) supplemented
with 5µM Fluo4/AM. After 20min of incubation, neurons were
rinsed twice and incubated for 10min in a Fluo-4/AM-free saline.
The imaging system consisted of an inverted Axio Observer A1
microscope equipped with a Fluar 40× oil immersion objective
lens (1.3 NA) (Carl Zeiss, France) and a CCD CoolSnap HQ2
camera (Princeton Instruments, Roper Scientific, France). A DG-
4 wavelength switcher (Princeton Instruments, Roper Scientific,
France) was used with λEX = 470 nm and λEM = 525 nm.
The setup was driven by MetaFluor (Universal Imaging, Roper
Scientific, France).
Radioligand Binding Studies
Radioligand binding assay was performed according to the
method of (Fischer et al., 1997) with slight modifications.
Binding experiments were conducted in 96-well microplates in
a total volume of 300 µL. The reaction mix included 30 µL
amounts of test compounds, 30 µL of radioligand and 240
µL of tissue suspension. Tissue (rat cortex) was homogenized
in 50 volumes of ice-cold 50mM Tris-HCl buffer with 10mM
ethylenediaminetetraacetic acid, pH 7.4 using an Ultra Turrax
T25B (IKA) homogenizer. The homogenate was centrifuged at
35,000 × g for 15min. The resulting pellet was resuspended in
the same quantity of buffer and centrifuged two more at the
same speed and frozen at −80◦C for at least 16 h and not more
than 2 weeks. For binding experiments, the membranes were
washed three times (homogenization in 25 volumes of cold 5mM
Tris-HCl (pH 7.4) with an Ultra-Turrax at maximum speed
for 30 s). The final pellet was resuspended in an appropriate
volume of buffer (10 mg/1ml) for use in the assay. Incubation
was performed in the presence of 10µM added glutamate and
glycine. The ligand, [3H]-MK-801 (spec. act. 40 Ci/mmol, Perkin
Elmer) was used at a final concentration of 5 nM. Non-specific
binding was determined in the presence of 10µMMK-801. After
a 2 h-incubation at room temperature, the reaction mix was
filtered immediately onto GF/B filter mate. Ten rapid washes
were performed with chilled 5mM Tris pH 7.4 buffer, using
an automated harvesting system Harvester-96 MACH III FM
(Tomtec, USA). Filter mates were dried at 37◦C in a forced air fan
incubator CLW 32 STD (Pol-Eko Aparatura, Poland) and then
solid scintillator was melted onto the filter mates at 100◦C for
5min. The radioactivity retained on the filter was counted in a
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MicroBeta2 LumiJET scintillation counter (PerkinElmer, USA).
The compounds analyzed ranged in concentration from 10−10 to
10−3M. All assays were done in duplicates.
Statistical Analysis
Statistical analysis of behavioral and Western blot studies was
performed using GraphPad Prism. We used one or two way
ANOVA when appropriate, followed by the Newman-Keuls post-
hoc test. Statistical significance was set at p < 0.05.
Analysis of recorded NMDA currents was carried out using
the pCLAMP 10 and Graphpad Prism software programs. The
obtained NMDA current values were analyzed using a one-
sample Wilcoxon Signed Rank Test against 100% separately for
hyperforin- and lanicemine.
Radioligand binding data were analyzed using iterative curve
fitting routines GraphPAD/Prism – San Diego, CA, USA). Ki
values were calculated from the Cheng and Prusoff (1973)
equation.
Calcium imaging data were analyzed by Student’s t-test.
Extracellular field potential recordings were analyzed by
Wilcoxon matched-pairs signed rank test.
RESULTS
Hyperforin Potentiates the Effects of
Lanicemine and MK-801 in the TST
As mentioned earlier, the functional relationship between
NMDAR and TRPC6 receptor has been described previously
(Qu Z. et al., 2017). Hyperforin and NMDAR antagonists’
antidepressant activity have also been previously reported
(Zanoli, 2004; Sanacora and Schatzberg, 2015). Both hyperforin
and NMDAR antagonists activate similar Ca2+-dependent
intracellular processes (Duman and Voleti, 2012; Heiser et al.,
2013). Therefore, we decided to investigate whether the
combined administration of hyperforin and lanicemine or MK-
801 can provide some beneficial antidepressant effects (stronger
effects or long-lasting activity). We choose lanicemine and MK-
801 two structurally different NMDAR antagonists. In this part
of our studies, we examined the antidepressant-like activity of
single active doses of hyperforin (2.5 and 5 mg/kg), lanicemine
(10 mg/kg) and a combined administration of hyperforin (2.5
or 5 mg/kg) and lanicemine (10 mg/kg) at three different
time points; 1, 24, and 72 h after treatment. Additionally, we
evaluated the effects of the combined administration of non-
active-doses of hyperforin (1 mg/kg) and lanicemine (2 mg/kg)
1 h after treatment. Both at the 1 and 24 h time points all
drugs evoked antidepressant activity (Figures 1A–C). Also, the
administration of a combined non-active dose of lanicemine (2
mg/kg) and non-active dose of hyperforin (1 mg/kg) induced
antidepressant-like activity after 1 h (Figure 1B). At the 72 h time
point, hyperforin and lanicemine administered alone did not
evoke any antidepressant effects, but a combined treatment with
hyperforin and lanicemine significantly reduced the immobility
time in the TST (Figure 1D).
In our preliminary studies combined treatment with
hyperforin (2.5 mg/kg) + lanicemine (10 mg/kg) significantly
reduced the immobility time in female mice both at the 1 h (TST)
and 72 h (FST) time points (Figure S1).
The effects observed in the TST were not associated with
increased locomotor activity (Table 2A). Moreover, hyperforin
(2.5 mg/kg) potentiated short-lasting antidepressant effects
induced by active dose of MK-801 (0.1 mg/kg) (Figure 1E). A
single dose of MK-801 did not evoke any effects in the TST
72 h after administration. In contrast, a combined administration
of hyperforin and MK-801 evoked an antidepressant response
(Figure 1F). MK-801 and hyperforin alone had no effect on
locomotor activity. However, a combined administration of MK-
801 and hyperforin decreased locomotor activity compared to the
MK-801 group (Table 2B).
Combined Treatment of a Single Dose of
Hyperforin and Lanicemine Reversed
Behavioral Disturbances in Mice Induced
by Chronic Corticosterone Administration
Because the TST is a simple behavioral screening test, in next
phase of the studies we wanted to find out if the beneficial
antidepressant-like activity of hyperforin and lanicemine seen
in the TST also occurs under complex conditions such as
those evoked by chronic corticosterone administration which
mimics stressful conditions where corticosterone is released in
response to stressful stimuli (Wilner, 2017). The hypothalamic
pituitary adrenal (HPA) axis is the central stress response
system. Disturbances in the functioning of the HPA axis have
been described in MDD patients and in mice subjected to
chronic stress (Keller et al., 2017; Wilner, 2017). We examined
the effects of combined administration of active doses of
hyperforin and lanicemine, lanicemine, hyperforin, or fluoxetine
given to control and Cort-treated mice. Doses of hyperforin
and lanicemine were selected on the basis of the respective
activity of each drug in the TST in naïve mice. Single doses of
hyperforin (2.5 mg/kg), lanicemine (10 mg/kg), fluoxetine (10
mg/kg) and lanicemine (10 mg/kg) + hyperforin (2.5 mg/kg)
were administered 7 days after Cort withdrawal. The TST and
splash test were conducted 72 and 144 h, respectively, after
drug administration (Figure 2A). Cort-treated mice displayed
increased immobility times compared to controls in the TST
(Figure 2B). Administration of hyperforin, lanicemine, and
fluoxetine did not reverse these effects. However, a combined
treatment with hyperforin and lanicemine abolished these
effects (Figure 2B). In the splash test, Cort-treated mice showed
decreased grooming time compared to controls (Figure 2C).
This depressive-like behavior was reversed only by a combined
treatment of hyperforin and lanicemine (Figure 2C). Next, 9
days (216 h) after drug administration, FST was performed
(Figure 2D). We observed increased immobility times in Cort-
treated mice and no effects of the antidepressant treatment
strategies (Figure 2D). Effects observed in the TST and FST were
specific because changes in locomotor activity were not noticed
(Table 2C).
Hyperforin Reversed MK-801 Induced
Effects in the Novel Object Recognition
Test
NMDAR antagonists, including ketamine, have been shown
to induce some cognitive impairment (Rajagopal et al., 2016).
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FIGURE 1 | The effect of combined administration of a single dose of hyperforin (Hyp) and NMDAR antagonists: lanicemine (Lan) and MK-801 in TST in mice.
(A,B) Lanicemine (2 or 10 mg/kg; i.p.) was administered 90min before the TST and 30min before hyperforin (1, 2.5, or 5 mg/kg; i.p.) treatment. ***p < 0.001 vs.
control, **p < 0.01 vs. control, *p < 0.05 vs. control, #p < 0.05 vs. lanicemine 10 + Hyp 5, n = 7–8; [A: F (3, 22) = 10.65; p = 0.0002], [B: F (3, 22) = 7.405;
p = 0.0013]. (C,D) Hyperforin and lanicemine were administered in the same way as in (A,B) but the TST was carried out 24 h (C) or 72 h (D) after hyperforin
treatment. **p < 0.01 vs. control, *p < 0.05 vs. control, n = 7–8; [C: F (5,38) = 4.376; p = 0.003], [D: F (5, 39) = 5.063; p = 0.0011]. (E,F) MK-801 (0.1 mg/kg; i.p.)
was administered 30min before hyperforin (2.5 mg/kg; i.p.), 1 h (E) or 72 h (F) after hyperforin treatment TST was carried out. ***p < 0.001 vs. control, **p < 0.01 vs.
control, #p < 0.05 vs. MK-801, n = 7–8; [E: F (2, 21) = 17.20; p = 0.0001], [F: F (2, 19) = 3.696; p = 0.0441]. All data was analyzed by one-way ANOVA and
Newman-Keuls multiple comparisons test. Values are expressed as mean ± S.E.M.
Cognitive deficits have also been identified in patients diagnosed
with MDD (Lam et al., 2014). Therefore, the improvement of
cognitive function is a very desirable feature for any novel or
potential antidepressant. The procognitive effects of hyperforin
have been previously reported (Klusa et al., 2001; Liu et al.,
2015). In the present studies, a single dose of hyperforin
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FIGURE 2 | The effect of the administration of single doses of hyperforin (Hyp), lanicemine (Lan), fluoxetine (Flx), and hyperforin + lanicemine (Hyp + Lan) on
behavioral disturbances induced by chronic corticosterone (Cort) treatment n = 9–11. Single doses of the following drugs: hyperforin (2.5 mg/kg; i.p.), lanicemine (10
mg/kg; i.p.), fluoxetine (10 mg/kg; i.p.) were used. (A) Experimental schedule of drug treatments and behavioral tests; (B) TST was carried out 72 h after treatment.
***p < 0.001 vs. control, ###p < 0.001 vs. cort. Two-way ANOVA showed cort effect [F (1,91) = 24.42; p = 0.0001], treatment effect [F (4,91) = 4.55; p = 0.002],
and interaction effect [F (4,91) = 3.248; p = 0.015]. (C) Splash test (SPT) was done 144 h after treatment. *p < 0.05 vs. control,
#p < 0.05 vs. cort. Two-way ANOVA
showed Cort effect [F (1,91) = 12.725; p = 0.00057], no treatment effect [F (4,91) = 1.252; p = 0.294] and interaction effect [F (4,91) = 3.058; p = 0.0205]. (D) FST was
carried out 216 h after treatment. *p < 0.05 vs. control, two-way ANOVA showed cort effect [F (1,91) = 4.398; p = 0.03875], no treatment effect [F (4,91) = 1.84;
p = 0.24578] and interaction effect [F (4,91) = 3.412; p = 0.012]. All data was analyzed by two-way ANOVA and Newman-Keuls multiple comparisons test. All values
are expressed as mean ± S.E.M.
(2.5, 5, 10 mg/kg) reversed cognitive disturbances in mice as
measured by the cognitive index evoked by a single dose of
MK-801 (0.3 mg/kg) in the NOR test (Figure 3A). Hyperforin,
administered alone did not have any effects on the recognition
index (Figure 3B).
Pretreatment With N-Methyl-D-Aspartic
Acid Abolished Antidepressant-Like
Activity of Hyperforin
A few in vitro studies have shown that hyperforin can block
the NMDAR (Chatterjee et al., 1999; Kumar et al., 2006).
Thus, we pretreated mice with NMDA and monitored them
for changes in the behavioral response to hyperforin in
the TST. Figure 4 shows that hyperforin (5 mg/kg) induced
antidepressant-like activity in the TST which was abolished
by the pretreatment with NMDA (75 mg/kg/body weight).
The NMDA dose used was selected based on previous
studies (Poleszak et al., 2007; Wolak et al., 2013). Also,
NMDA/CNS related responses after i.p. administration have
been described by Budziszewska et al. (1998). Hyperforin given
alone and in combination with NMDA decreased locomotor
activity in comparison to control group. Therefore, decreased
locomotor activity is not related to NMDA co-administration
(Table 2D).
Administration of Larixyl Acetate and
MK-2206 Abolished Effects of Hyperforin
Observed in the TST
Results obtained from previous in vitro studies indicated that
hyperforin-induced cellular effects are Ca2+-dependent (Leuner
et al., 2007; Tu et al., 2009, 2010), thus we wanted to
find out whether Ca2+-dependent processes are involved in
the behavioral response of hyperforin. In particular, TRPC6
channels and AKT kinase are thought to be involved in
these effects. Preinjection with larixyl acetate a potent TRPC6
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FIGURE 3 | The effect of pretreatment with glutamate system modulator on hyperforin activity in the NOR in mice. (A,B) Hyperforin (2.5, 5, 10 mg/kg; i.p.) was
administered 60min before the first session. MK-801 (0.3 mg/kg; i.p.) was administered 30min before the first training session of the NOR test. ###p < 0.001 vs.
control, ***p < 0.001 vs. MK-801, n = 6–8; [A: F (4,32) = 70.04; p = 0.0001], [B: F (4,30) = 36.08; p = 0.0001]. All data was analyzed by one-way ANOVA and
Newman-Keuls multiple comparisons test. All values are expressed as mean ± S.E.M.
FIGURE 4 | The effect of pretreatment with glutamate system modulator on
hyperforin activity in the TST in mice. NMDA (75 mg/kg; i.p.) was administered
15min before hyperforin (2.5 mg/kg; i.p.). TST was carried out 60min after
hyperforin administration. **p < 0.01 vs. control, #p < 0.05 vs. hyperforin,
n = 5–7; [F (3,22) = 4.957; p = 0.0089]. All data was analyzed by one-way
ANOVA and Newman-Keuls multiple comparisons test. All values are
expressed as mean ± S.E.M.
antagonist (Urban et al., 2016) (10 nM/2 µL) and pretreatment
with Akt 1/2/3 kinase inhibitor - MK-2206 (Cheng et al.,
2012) (20 mg/kg) abolished the hyperforin induced effects in
the TST (Figures 5A–C). However, these results should be
interpreted carefully because hyperforin+ larixyl acetate induced
decreased locomotor activity when compared to hyperforin
group (Table 2E).
Hyperforin Does Not Affect NMDAR
Synaptic Currents and NMDA Component
of the Field Potential
Some studies have shown that hyperforin is able to influence
NMDAR function (Chatterjee et al., 1999; Kumar et al., 2006).
Thus, our next set of studies was focused on evaluating the
effects of hyperforin and lanicemine on NMDAR-mediated
synaptic currents resulting from electrical stimulation. As we
described earlier, the behavioral effects of hyperforin were
abolished by pretreatment with larixyl acetate and MK-2206
(TRPC6 and Akt 1/2/3 kinase inhibitors, respectively). Thus,
for patch clamp studies, hyperforin’s concentration (0.5µM)
was selected based on its potential to activate TRPC6 receptors
(0.3 to 10µM) (Tu et al., 2010; Heiser et al., 2013; Leuner
et al., 2013). Electrophysiological studies showed that lanicemine
(2µM) significantly attenuated the NMDAR current while
hyperforin had no effect (Figure 6). Moreover, there was no
effect of acute hyperforin (1µM) administration on NMDA
receptor component amplitude (101% vs. 96%, p > 0.2)
(Figure S2).
The Affinity of Lanicemine and Hyperforin
for NMDA Receptor Channel
The radioligand receptor binding studies (3H-MK801 as ligand)
demonstrated no affinity for NMDA receptor channel of
hyperforin In contrast lanicemine shows affinity for NMDAR
receptors (Ki = 1.067× 10
−5) (Figure S3).
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FIGURE 5 | The effect of pretreatment with Ca2+-dependent process
modulators on hyperforin activity in the TST in mice (A) MK-2206 (Akt1/2/3
kinase inhibitor: 20 mg/kg; i.p.) was administered 15min before hyperforin (2.5
and 5 mg/kg; i.p.). TST was carried out 60min after hyperforin treatment.
**p < 0.01 vs. control, ##p < 0.01 vs. hyperforin 2.5, ###p < 0.001 vs.
hyperforin 5, n = 6–8; [F (5, 34) = 7.144; p = 0.001]. (B) Experimental schedule
of drug treatments and behavioral tests. (C) Larixyl acetate (TRPC6
antagonist: 10 nM/2 µL; i.c.v.) was injected 15min before hyperforin (2.5
mg/kg; i.p.) and 60min after hyperforin treatment the TST was carried out
*p < 0.05 vs. control, #p < 0.05 vs. hyperforin, n = 9–10; [F (3, 35) = 3.892;
p = 0.0168]. All data was analyzed by one-way ANOVA and Newman-Keuls
multiple comparisons test. All values are expressed as mean ± S.E.M.
FIGURE 6 | Effects of hyperforin/Lanicemine on layer V to later II/III NMDA
synaptic transmission. (A,B) Application of Lanicemine markedly reduced the
NMDA current, whereas hyperforin had no effect (p = 0.0313, median
51.63%, n = 6 vs. p = 0.8750, median 94.8, n = 4, respectively, Wilcoxon
Signed Rank Test), *p < 0.05 vs. Hyp. Below, (C) Sample raw NMDA currents
recorded under the two conditions, dotted line is for baseline currents.
The Effects of Hyperforin, Lanicemine, and
Combined Administration of Hyperforin
and Lanicemine on the Expression of
Selected Proteins in the Frontal Cortex
The antidepressant-like activity of NMDAR antagonists is related
to the enhanced synthesis of synaptic proteins and neurotrophins
(Duman et al., 2016). Hyperforin can activate signaling pathways
involved in the processes of neuroplasticity in vitro (Heiser et al.,
2013). Therefore, we determined the levels of the GluA1 subunit
of AMPA receptors, synapsin I, BDNF, and CREB after treatment
of mice with either hyperforin or lanicemine or a combination of
both drugs (Figures 7A,B,G,H). This treatment strategy did not
significantly alter p-CREB/CREB levels (Figure 7C) but elevated
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BDNF (Figure 7D) in the frontal cortex (1 h after hyperforin
and 1.5 h after lanicemine administration). A single dose of
either hyperforin or lanicemine did not alter the expression of
synapsin I and GluA1 (Figures 7E,F). In contrast, the combined
administration of hyperforin and lanicemine increased the levels
of both proteins (Figures 7E,F). After 72 h, a combination of
hyperforin and lanicemine did not alter p-CREB/CREB levels
(Figure 7I); however, lanicemine and hyperforin + lanicemine
significantly increased the levels of BDNF in the test animals
compared to controls (Figure 7J). The levels of other proteins
(synapsin I, GluA1) remained unchanged 72 h after treatment
(Figures 7K,L).
Lanicemine Potentiates Intracellular Ca2+
Responses Triggered by Hyperforin
To better delineate the effects of lanicemine, Ca2+ imaging
experiments were carried out on primary cultures of cortical
neurons loaded with the fluorescent Ca2+ probe Fluo4. The
external application of hyperforin (1µM) generated specific
Ca2+ responses as illustrated in (Figure 8) (horizontal gray bar)
(Chauvet et al., 2015, 2016). In some instances, lanicemine
(5µM) was added first (Figure 8, horizontal hatched bar). This
had no effect on the basal Fluo-4 fluorescence, suggesting that
basal levels of Ca2+ were not perturbed. However, hyperforin-
induced Ca2+ responses were increased by a 4min pre-
incubation with lanicemine.
DISCUSSION
A rapid onset of action and long-lasting activity after a single
dose of a drug are the most desired features sought for in
novel antidepressants. These effects have been observed in
rodents after treatment with ketamine and its metabolite, 2R,6R-
hydroxynorketamine (Li et al., 2010, 2011; Autry et al., 2011;
Zanos et al., 2016; Yang et al., 2017). A similar profile of
antidepressant-like activity has also been described for a few
NMDAR modulators (Ro 25-6981 and GLYX-13) (Li et al., 2010,
2011; Liu et al., 2017).
In the present study, we showed that a combination of
a single dose of hyperforin and the NMDAR antagonist
lanicemine evoked long-lasting antidepressant effects 72 h
after administration in both naïve and chronic Cort-treated
male mice. Additionally, in our preliminary study, we also
observed the long-lasting antidepressant-like effects of
hyperforin+lanicemine in naïve female mice. It seems that
this interaction is not exclusive to lanicemine and hyperforin
because the co-administration of hyperforin and MK-801,
another NMDAR antagonist also induced the same long-
lasting antidepressant-like responses in the TST in naïve mice.
Lanicemine, MK-801, and hyperforin by themselves did not
elicit long-lasting antidepressant effects after 72 h. It should be
mentioned that we selected only a single dose each of lanicemine
and MK-801; it is thus possible that the induction of the
long-lasting antidepressant effects may be dose-dependent. As
reported previously, the exceptional profiles of antidepressant-
like activity of ketamine and NMDAR modulators are related
to the immediate activation of molecular processes that lead to
enhanced neuroplasticity mainly in the Hp and PFC (Li et al.,
2010, 2011; Ardalan et al., 2017). These two brain structures
are functionally impaired in MDD (Duman and Voleti, 2012;
Duman et al., 2016). Fast and long-acting antidepressants
enhanced the expression of synaptic markers like synapsin I or
the GluA1 subunit of glutamate AMPA receptors (Li et al., 2010;
Liu et al., 2017). In our study, hyperforin or lanicemine treatment
did not alter the levels of synapsin I and GluA1 subunit in the
frontal cortex of mice. However, a combined administration of
the two compounds elevated the levels of synapsin I and GluA1
subunit after 1 h. Enhanced expression of GluA1 and synapsin I
was not sustained 72 h after hyperforin + lanicemine treatment.
These results may suggest that elevated synaptic protein synthesis
is not involved in the long-lasting effects induced by hyperforin
+ lanicemine.
Another well-documented explanatory hypothesis of the
mechanism of action of long-acting drugs is related to the
enhanced activation of the BDNF signaling pathway. Results
obtained from several studies have indicated that BDNF
plays an important role in the mechanism of action of
long-acting antidepressants. Autry et al. (2011) and Zanos
et al. (2016) showed that a single dose of ketamine or its
metabolite 2R,6R-hydroxynorketamine increased the synthesis
of BDNF in the mouse Hp. Both ketamine and GLYX-13
have been shown to induce the release of BDNF in cortical
neurons (Lepack et al., 2014, 2016). We found that hyperforin,
lanicemine, and hyperforin + lanicemine enhanced BDNF
expression 1 h after administration. Surprisingly, while only
combined doses of lanicemine and hyperforin induced long-
lasting antidepressant effects, lanicemine alone and lanicemine
+ hyperforin enhanced BDNF levels 72 h after administration.
Because lanicemine similar to hyperforin + lanicemine also
enhanced BDNF synthesis 72 h after treatment, these results may
suggest that the enhanced synthesis of BDNF is not sufficient
to explain the long-lasting antidepressant effects observed only
after hyperforin+lanicemine treatment. As indicated in a few
other studies, the relationship between BDNF synthesis and
antidepressant-like activity may be more complicated than
originally thought (Song et al., 2017). There are indications
that BDNF may be synthesized in different parts of neural
cells (glia vs. neurons or presynaptic vs. synaptic elements).
These distinctions may underlie the biological role of BDNF
in the neural system (Song et al., 2017). Therefore, it is
possible that the significance of BDNF in the antidepressant-
like activity of these compounds is not only related to its
levels but also related to the site of synthesis. We should also
mention that hyperforin is an agonist of TRPC6 receptors.
Zhou et al. (2008) described the relationship between BDNF
signaling pathway and TRPC6 receptors and showed that
TRPC6 receptors mediated the influence of BDNF on spine
formation in rat hippocampal cultures. The involvement of
TRPC6 receptors in the antidepressant-like activity of hyperforin
was implicitly revealed in our behavioral studies. We showed that
pretreatment with larixyl acetate (TRPC6 antagonist) abolished
the antidepressant-like effects induced by hyperforin in the TST.
Also, pretreatment with MK-2206 (Akt1/2/3 kinase inhibitor)
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FIGURE 7 | The effect of the administration of single doses of hyperforin (Hyp), lanicemine (Lan) and hyperforin + lanicemine (Hyp + Lan) on the expression of
p-CREB, total CREB, BDNF, Synapsin I, and GluA1 subunit of AMPA receptors. (A) Experimental schedule of drug treatments. (B) Representative blots. (C–F)
(Continued)
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FIGURE 7 | lanicemine (10 mg/kg) was administered 90min and hyperforin (2.5 mg/kg) 60min before TST. (G) Experimental schedule of drug treatments.
(H) Representative blots. (I–L) lanicemine was administered 72.5 h and hyperforin 72 h before TST. Frontal cortex was dissected immediately after TST.
(C) p-CREB/CREB [F (3,28) = 0.4795; p=0.6992]. (D) BDNF, [F (3,28) = 4.886; p = 0.0074]. (E) Synapsin I, [F (3,24) = 3.573; p = 0.028]. (F) GluA1 [F (3,28) = 3.656,
p = 0.0243]. *p < 0.05 vs. control, **p < 0.01 vs. control, #p < 0.05 vs. Hyp + Lan, $p < 0.05 vs. Hyp + Lan. Effects observed 72 h after treatment: (I)
p-CREB/CREB, [F (2,20) = 2.734; p = 0.0892]. (J) BDNF [F (2,21) = 3.764; p = 0.0401]. (K) Synapsin I, [F (2,21) = 0.2062; p = 0.8153]. (L) GluA1, [F (2,21) = 0.3509;
p = 0.7081]. *p < 0.05 vs. control. All data was analyzed by one-way ANOVA and Newman-Keuls multiple comparisons test. All values are expressed as mean ±
S.E.M.
completely abolished hyperforin’s effects observed in the TST. In
other words, pharmacological blockade of TRPC6 and one of its
main intracellular effectors Akt kinase inhibits the antidepressant
effects of hyperforin induced in mice. These results are in
agreement with in vitro studies which have shown that the
biological effects of hyperforin are related to the activation of the
TRPC6 channel (Leuner et al., 2007; Tu et al., 2010) followed by
a subsequent activation of the Akt kinase (Heiser et al., 2013).
Therefore, it is possible that the antidepressant-like activity
of combined doses of hyperforin + lanicemine is dependent
on crosstalk between the blockade of NMDAR, activation of
TRPC6 receptors, and BDNF pathways. Additionally, (Zhou
et al., 2008) showed that TRPC6 regulates synaptic plasticity
through the CREB signaling pathway. It is also well-established
that the synthesis of BDNF is dependent on the phosphorylation
of CREB (Nibuya et al., 1996). So in the next step of our study, we
evaluated the effects of treatments on p-CREB/CREB ratio levels.
We only observed a trend toward an increase in the levels of p-
CREB/CREB ratio 1 h after hyperforin + lanicemine treatment.
Thus, the involvement of CREB in the biosynthesis of BDNF after
hyperforin + lanicemine requires further detailed and precise
studies.
Second possible hyperforin’s antidepressant mechanism of
action reported previously is related to blockade of NMDAR
(Kumar et al., 2006). Whole cell patch clamp studies showed
that hyperforin at 0.5µM concentration did not change cortical
NMDAR currents. Moreover, there was no effect of hyperforin
(1µM) administration on the NMDA component of the field
potential. Furthermore, radioligand binding studies indicated
that hyperforin had no affinity for the 3H-MK-801 labeled site
of the NMDAR. Thus, in these particular conditions hyperforin
does not interfere with NMDAR. Concomitantly, we have shown
that pretreatment with NMDA abolished antidepressant-like
activity of hyperforin in TST. To answer the question whyNMDA
administration blocks the antidepressant-like effect of hyperforin
in TST in mice requires further investigation.
Because the biosynthesis and release of synaptic proteins
like GluA1 and synapsin I, and BDNF and their release is
strictly coupled to the activation of cellular processes that
require elevated levels of intracellular Ca2+ (Duman et al.,
2016; Finkbeiner, 2016) we sought to find out if the combined
administration of hyperforin and lanicemine evoked different
intracellular Ca2+ responses than the administration of either
lanicemine or hyperforin alone. Calcium imaging studies
revealed that lanicemine potentiated hyperforin-induced Ca2+
signals. However, the mechanism by which lanicemine regulates
hyperforin-dependent Ca2+ responses is currently unknown and
requires further studies.
FIGURE 8 | Representative Ca2+ responses from 2 different cells in response
to the application of 1µM hyperforin alone (gray line) and 4min after the
addition of 5µM Lanicemine (black line). Note that Lanicemine remained
during stimulation with hyperforin. n = 112 and 126 cells with hyperforin and
hyperforin + Lanicemine, respectively. Hyperforin-induced Ca2+ responses
were increased by 35 ± 6 % (p < 0.05, Student’s t-test) by a 4min
pre-incubation with lanicemine.
To summarize, the results obtained in this study showed
that treatment with a single active dose of hyperforin and
lanicemine induced a long-lasting antidepressant-like activity
in mice. These effects were observed in both naïve and
corticosterone-treated male mice. Hyperforin + lanicemine
effects were sustained for up to 6 days after treatment.
Interestingly, our preliminary studies also showed that combined
single doses of hyperforin + lanicemine also induced long-
lasting effects in naïve female mice in the TST. The induction
of antidepressant-like effects in both male and female mice is
a very desirable feature of any potential, novel antidepressant
because sex-related responses to antidepressant therapy have
been postulated frequently (Khan et al., 2005). The potential
benefit of administration hyperforin + lanicemine is associated
with hyperforin’s potential to improve cognitive activity.
Because hyperforin attenuates cognitive disturbances induced
by MK-801 it can be administered with other NMDAR
antagonists which induce cognitive impairments. Furthermore,
MDD with cognitive dysfunction has been described (Lam
et al., 2014). Therefore, combined doses of hyperforin +
lanicemine can be a useful potential strategy in the treatment of
depression including cognitive disturbances. Another important
question is what kinds of biological mechanisms are involved
in hyperforin + lanicemine induced mechanism of action.
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Calcium imaging studies have shown that the biological
interaction between hyperforin + lanicemine is a Ca2+-
dependent process. Our biochemical and behavioral studies
indicated that the main mechanism of action can be associated
with crosstalk between the TRPC6 receptor and the BDNF
signaling pathway. However, further studies are required
to better understand the biological foundations of these
interactions.
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